NFL Coach Diagnosed with Leukemia

Chuck Pagano, the first-year coach for the NFL's Indianapolis Colts, has been diagnosed with acute promyelocytic leukemia (APL), according to the Indianapolis Star.

Fatigue and bruising were signs something was wrong

Colts owner Jim Irsay told the press on Monday morning that the coach "was feeling some fatigue over the last few weeks and noticed some bruising on his body that he first thought could have been from contact on the field, or coaching, or playing with his grandkids. Through talking to his wife, Tina, she said, 'You need to get that checked out, because the bruising appears to be more and more prominent.' We had the coach get fully evaluated, and the conclusion was that he did have leukemia."

Acute promyelocytic leukemia

Acute promyelocytic leukemia is regarded as a variant of acute myeloid leukemia--specifically, the most malignant and aggressive form of AML. Without treatment, survival times are measured in months or sometimes just weeks.

Treatment can be highly successful, however, if caught early enough. Treatment unfolds over the span of one to two years and it is measured in three basic stages: Induction (chemotherapy), followed by consolidation therapy (in which the patient is considered cancer-free but treatment is added to "mop up" the remaining cancer cells) and in some cases maintenance therapy.

Provided treatment begins immediately, three-survival figures range as high as 70 percent.

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap